AstraZeneca Imfinzi Cuts Death Risk by 58%, 42% in Lung, Bladder Cancer Studies

04:26 AM EDT, 10/26/2026 (MT Newswires) -- AstraZeneca (AZN) said Saturday two phase 3 trials showed its cancer drug Imfinzi helped patients with extensive-stage small cell lung cancer and muscle-invasive bladder cancer, cutting the risk of death by 58% when combined with Amgen's (AMGN) Imdelltra in the lung study and by 42% when paired with enfortumab vedotin in the bladder study. Patients with lung cancer on the combination lived a median of 21.1 months versus 12.7 months for Imfinzi alone, with 79% alive at one year against 53%, AstraZeneca said. Separately, the company also said Imfinzi given before and after surgery with enfortumab vedotin lowered the risk of recurrence by 49% and the risk of death by 42% in muscle-invasive bladder cancer 78% of patients on that combination were alive at two years versus 69% on standard care, it said.